Expression and Clinicopathologic Correlation of Basal Cytokeratins in Breast Cancer

Seyed, Rabia (2015) Expression and Clinicopathologic Correlation of Basal Cytokeratins in Breast Cancer. Masters thesis, PSG Institute of Medical Sciences and Research, Coimbatore.


Download (19MB) | Preview


INTRODUCTION: Treatment for breast cancer is based on the expression of the immunomarkers such as ER, PR and HER2/neu. Cases which are negative to all the three immunomarkers, are called Triple Negative Breast Cancers (TNBC) and they have a poor prognosis. Recent studies have shown that some of the TNBCs express cytokeratins CK 5/6 (subcategorizing them as basal-like breast cancers) and these respond well to anthracycline-based chemotherapy. AIM AND OBJECTIVES: To study the expression of basal cytokeratins CK 5/6 in breast carcinomas reported in our centre and to correlate with histological type, grade, size, clinical features and ER, PR and HER2/neu status. METHODS: Tissues of 44 cases of breast carcinoma diagnosed between June 2009 and May 2014 were retrieved. Immunohistochemical staining for CK 5/6 was done and it was correlated with parameters such as histopathological type, grade, size, invasion and ER, PR and HER2/neu status. RESULTS: Eight of the breast carcinomas (18%) were categorized as Triple Negative Breast Cancers (TNBC) as they were negative for ER, PR and HER2/neu. Four of the TNBCs (50%), were positive for CK 5/6. Significant statistical correlation was observed between the size of the tumour and positive CK 5/6 expression. All CK 5/6 positive cases were of high grade. CONCLUSION: The routine use of CK 5/6 is recommended in all cases of TNBCs, as 50% of them are positive for these markers. Patients in this subcategory could benefit from anthracycline-based chemotherapy.

Item Type: Thesis (Masters)
Uncontrolled Keywords: Triple Negative Breast Cancers ; Cytokeratin 5/6 ; basal-like breast carcinoma.
Subjects: MEDICAL > Pathology
Depositing User: Punitha K
Date Deposited: 19 May 2018 15:16
Last Modified: 22 May 2018 17:53

Actions (login required)

View Item View Item